Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®
Drug Safety · 2025
DOI: 10.1007/s40264-025-01546-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Safety, 2025. Verfasst von Paul Gautier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospi…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Pharmacovigilance, Neoplasms, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Université de Toulouse.
Abstract (Originalsprache)
INTRODUCTION: Use of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) has significantly increased due to their cardiovascular benefits. Whether SGLT-2is increase risk of cancer has been of concern since first clinical trials, but this question remains unclear because of methodological limitations in previous studies. METHODS: We conducted a disproportionality analysis using Vigibase® between 2014 and 2023 to estimate the association between SGLT-2i use and the risk of reporting of different subtypes of cancers, compared with glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors. RESULTS: Among 644 reported cases of cancer associated with SGLT-2i use, 427 (66.3%) were male, with a mean age of 66.5 ± 9.7 years. Sodium-glucose cotransporter 2 inhibitors showed increased reporting odds ratio for bladder cancer (ROR 4.46, 95% CI 3.23-6.17) and kidney cancer (ROR 1.84, 95% CI 1.25-2.69), but not for all other cancer subtypes. CONCLUSION: In this disproportionality analysis with a hypothesis-generating approach, SGLT-2is are associated with an increased risk of reporting bladder and kidney cancer. There is a need of an urgent clarification of this signal with further long-term observational studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), 37 Allées Jules Guesde, 31000, Toulouse, France.
- Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Centre d'Investigation Clinique 1436, Toulouse University Hospital, Toulouse, France.
- Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059, Toulouse, France.
- Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), 37 Allées Jules Guesde, 31000, Toulouse, France. francois.m…
- Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Centre d'Investigation Clinique 1436, Toulouse University Hospital, Toulouse, France. francois.montastruc@univ-tlse3.fr.
Förderung
- Université de Toulouse
Zitieren
APA
Gautier, P., Elbaz, M., Bouisset, F., Despas, F., & Montastruc, F. (2025). Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®. Drug Safety. https://doi.org/10.1007/s40264-025-01546-5
Vancouver
Gautier P, Elbaz M, Bouisset F, Despas F, Montastruc F. Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®. Drug Safety. 2025. doi:10.1007/s40264-025-01546-5
BibTeX
@article{Gautier2025,
author = {Gautier, Paul and Elbaz, Meyer and Bouisset, Frédéric and Despas, Fabien and Montastruc, François},
title = {Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®},
journal = {Drug Safety},
year = {2025},
doi = {10.1007/s40264-025-01546-5}
}
EUVIMED